BCPCNasdaqChemicals & Allied ProductsFiscal year ends December 31
BALCHEM CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 23, 2026
$170.42−0.31 (-0.18%)
Close on Oct 19, 2026
- Market cap
- $5.49B
- P/E (TTM)
- 33.5
- Dividend yield
- 0.56%
BALCHEM CORP revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Nutrition and Health | $176.89M | $171.63M | $166.07M | $174.09M | $160.77M | $158.46M | $147.30M | $152.28M | $147.93M | $152.74M | $137.97M | $144.46M | 62.3% | +10.0% |
| Animal Nutrition and Health | $64.45M | $62.19M | $61.17M | $56.38M | $56.03M | $57.28M | $58.33M | $52.91M | $49.56M | $53.92M | $58.16M | $53.94M | 22.7% | +15.0% |
| Specialty Products | $40.51M | $34.73M | $34.83M | $35.68M | $37.19M | $33.28M | $32.85M | $33.19M | $35.09M | $31.61M | $31.00M | $30.00M | 14.3% | +8.9% |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human Nutrition and Health | $42.38M | $40.02M | $36.76M | $40.83M | $38.34M | $37.97M | $33.76M | $35.58M | $33.37M | $33.26M | – | – | +10.5% |
| Specialty Products | $12.89M | $11.94M | $10.51M | $11.53M | $11.27M | $9.59M | $9.96M | $10.52M | $11.23M | $8.20M | – | – | +14.4% |
| Animal Nutrition and Health | $5.23M | $5.69M | $6.22M | $3.71M | $3.51M | $5.24M | $5.73M | $3.53M | $2.69M | $2.06M | – | – | +48.7% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Sales Revenue | $283.36M | $270.22M | $263.09M | $267.08M | $255.04M | $250.06M | $239.57M | $239.52M | $233.73M | $239.13M | $228.44M | $229.27M | 99.8% | +11.1% |
| Royalty Revenue | $634.00K | $493.00K | $525.00K | $480.00K | $426.00K | $458.00K | $431.00K | $418.00K | $355.00K | $533.00K | $255.00K | $674.00K | 0.2% | +48.8% |
| Consignment | – | – | – | – | – | – | – | – | – | – | – | $4.32M | – | – |
| Co-manufacturing | – | – | – | – | – | – | – | – | – | – | – | $6.92M | – | – |
| Product Sales Revenue | – | – | – | – | – | – | – | – | – | – | – | $229.27M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $205.19M | $197.38M | $188.96M | $198.06M | $186.71M | $185.72M | $181.53M | $181.99M | $177.69M | $182.09M | $174.50M | $176.77M | 72.3% | +9.9% |
| Foreign Countries | $78.80M | $73.33M | $74.66M | $69.49M | $68.76M | $64.80M | $58.47M | $57.95M | $56.39M | $57.57M | $54.20M | $53.18M | 27.7% | +14.6% |
From the segment and revenue-disaggregation notes of Balchem's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.